Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Post-Mkt 11-06 19:23:06 EST

8.75

+0.71

+8.83%

盘后8.67

-0.08-0.90%

18:37 EST

High8.75	Low8.06	Vol954.02K
Open8.24	D1 Closing8.04	Amplitude8.58%
Mkt Cap669.54M	Tradable Cap525.50M	Total Shares76.52M
T/O8.13M	T/O Rate1.59%	Tradable Shares60.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":8.75,"timestamp":1793998800000,"preClose":8.04,"halted":0,"volume":954018,"hourTrading":{"tag":"盘后","latestPrice":8.6714,"preClose":8.75,"latestTime":"18:37 EST","volume":8220,"amount":72352.45644,"timestamp":1794008252370,"change":-0.0786,"changeRate":-0.008983,"amplitude":0.024},"delay":0,"changeRate":0.0883084577114429,"floatShares":60056800,"shares":76518600,"eps":-1.438968,"marketStatus":"Post-Mkt","change":0.71,"latestTime":"11-06 19:23:06 EST","open":8.24,"high":8.75,"low":8.06,"amount":8131025.770686,"amplitude":0.085821,"askPrice":8.75,"askSize":1,"bidPrice":8.67,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.438968,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1794013200000},"marketStatusCode":4,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":8.04,"preHourTrading":{"tag":"盘前","latestPrice":8.23,"preClose":8.04,"latestTime":"09:29 EST","volume":290,"amount":2339.1385499999997,"timestamp":1793975399505,"change":0.19,"changeRate":0.023632,"amplitude":0.023632},"postHourTrading":{"tag":"盘后","latestPrice":8.6714,"preClose":8.75,"latestTime":"18:37 EST","volume":8220,"amount":72352.45644,"timestamp":1794008252370,"change":-0.0786,"changeRate":-0.008983,"amplitude":0.024},"volumeRatio":0.665408,"impliedVol":1.013,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/CADL","defaultTab":"news","newsList":[{"id":"2681886735","title":"Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2681886735","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681886735?lang=en_us&edition=fundamental","pubTime":"2026-11-06 22:00","pubTimestamp":1793973600,"startTime":"0","endTime":"0","summary":"Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/06/3397542/0/en/candel-therapeutics-presents-sitc-2026-data-highlighting-systemic-immune-activation-and-survival-outcomes-across-clinical-stage-portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011746.SGD","BK4539","CADL","IE00BYTNYN87.SGD","BK4231","ADT","BK4192","IDNA","BK1103","DNA","IE0003851619.USD","032820.KR","SEC.AU","IE00BYQNZ168.SGD","BK4080","BLA.AU","BK4165","SEA","DNA.AU","BK7078","IE0003795394.USD","IE00B12V2V27.USD","BK1541","ADT.AU","LU1880383366.USD","BK9077","01308","SITC","BK7095","BK4139","BOAT","LU1880383440.USD","BK4109","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681000059","title":"Candel Therapeutics Grants General Counsel Maria Ostrovsky Options to Buy 315,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2681000059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681000059?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:40","pubTimestamp":1793914844,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants General Counsel Maria Ostrovsky options to buy 315,000 sharesCandel Therapeutics granted General Counsel Maria Ostrovsky stock options to purchase 315,000 common shares on N","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL48lJ73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BQXX3F31.USD","LU2095319765.USD","BK4539","BK4112","LU0314104364.USD","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","SG9999014013.SGD","BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","BK4588","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","CADL","LU2210149790.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681000835","title":"Candel Therapeutics Files Initial Beneficial Ownership Statement for General Counsel Maria Ostrovsky","url":"https://stock-news.laohu8.com/highlight/detail?id=2681000835","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681000835?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:26","pubTimestamp":1793913965,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Files Initial Beneficial Ownership Statement for General Counsel Maria OstrovskyCandel Therapeutics General Counsel Maria Ostrovsky filed an initial statement of beneficial ownersh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDLLFLth:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681004120","title":"Candel Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681004120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681004120?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:05","pubTimestamp":1793912713,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA27JJFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680798069","title":"Candel Therapeutics Grants Options on 107,600 Shares to Four New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680798069?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:12","pubTimestamp":1793653924,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Grants Options on 107,600 Shares to Four New EmployeesCandel Therapeutics granted four new employees stock options to purchase 107,600 shares on Oct. 31, 2026.The options carry an ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL6DLgH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","BK4588","IE00BQXX3C00.GBP","SG9999014021.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","NDAQ","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4539","BCDF","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680964798","title":"Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680964798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680964798?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:05","pubTimestamp":1793653500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA8C1BVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680793263","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680793263","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680793263?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:05","pubTimestamp":1793653500,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Nov.  02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/02/3393715/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LCLG","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679400798","title":"Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2679400798","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679400798?lang=en_us&edition=fundamental","pubTime":"2026-10-29 21:00","pubTimestamp":1793278800,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/29/3391303/0/en/candel-therapeutics-announces-late-breaking-abstract-accepted-for-poster-presentation-at-the-sitc-2026-annual-meeting-featuring-aglatimagene-besadenovec-data-in-localized-prostate-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01308","DNA","LU1880383366.USD","GDOC","LU1880383440.USD","MEDX","IE00BYQNZ168.SGD","SEA","BK4121","HYLG","BK1541","BK1103","SITC","BK4539","IE00BYTNYN87.SGD","BK4139","SG9999011746.SGD","BK4231","IE0003851619.USD","IE00B12V2V27.USD","CADL","IE0003795394.USD","NVIB","BK4080","BOAT","BK4109","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678117296","title":"Candel Therapeutics to Present at November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2678117296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678117296?lang=en_us&edition=fundamental","pubTime":"2026-10-27 20:05","pubTimestamp":1793102700,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/27/3388965/0/en/candel-therapeutics-to-present-at-november-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677991486","title":"Candel Therapeutics Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2677991486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677991486?lang=en_us&edition=fundamental","pubTime":"2026-10-23 04:42","pubTimestamp":1792701720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677183968","title":"Candel Therapeutics Names Maria Ostrovsky General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2677183968","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677183968?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:11","pubTimestamp":1792671108,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Names Maria Ostrovsky General CounselCandel Therapeutics appointed Maria Ostrovsky as general counsel, effective November 3, 2026.Ostrovsky most recently served as senior vice pres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nNDL1sLjbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00B64PRP62.GBP","BK4539","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BQXX3D17.EUR","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4588","IE00BQXX3F31.USD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014021.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","BCDF","IE00BKPKM429.USD","CADL","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677968323","title":"Candel Therapeutics Appoints Maria Ostrovsky as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2677968323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677968323?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:05","pubTimestamp":1792670700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nTUA2VKR36:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672712822","title":"Candel Therapeutics to Present NSCLC Aglatimagene Besadenovec Study Data at SITC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672712822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672712822?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946058,"startTime":"0","endTime":"0","summary":"Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026Candel Therapeutics set two poster presentations at SITC’s 41st Annual Meeting, November 4-8, 2026 in Phoenix.Resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLfkxys:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4139","BK4539","BCDF","LU2210150020.SGD","BK4588","BK4585","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","CADL","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","SG9999014021.USD","LU0314104364.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672591712","title":"Candel Therapeutics to Present at the SITC 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672591712","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672591712?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946000,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","DNA","BK1541","IE00BYTNYN87.SGD","IE0003795394.USD","BK4139","CADL","IDNA","SEA","LU1880383440.USD","BK4080","IE00BYQNZ168.SGD","MEDX","IE00B12V2V27.USD","BK4539","SG9999011746.SGD","SITC","BK1103","BK4231","NVIB","GDOC","IE0003851619.USD","LU1880383366.USD","01308","HYLG","BK4109","BOAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672076495","title":"Candel Therapeutics Grants Inducement Stock Options for 85,900 Shares to Four New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2672076495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672076495?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885146,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants inducement stock options for 85,900 shares to four new employeesCandel Therapeutics granted inducement stock options covering 85,900 common shares to four new employees on S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL2nn0Fb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","IE00BQXX3F31.USD","BK4539","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","SG9999014005.SGD","BK4588","BK4585","CADL","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BK4139","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00BN0W2V16.EUR","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672605764","title":"Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672605764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672605764?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUABBQHGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672640197","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672640197","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672640197?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885100,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373373/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754023","title":"Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754023","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754023?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856377,"startTime":"0","endTime":"0","summary":"Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival for aglatimagene plus valacyclovir after ICI failureCandel Therapeutics reported final Phase 2a results in advanced NS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Rphwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4539","BK4585","BK4139","LU0314104364.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4112","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","NDAQ","BK4588","SG9999014021.USD","CADL","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754046","title":"Candel Therapeutics - 69% of Patients with Multiple Lesions Show Systemic Clinical Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754046?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672275404","title":"Candel Therapeutics - Aglatimagene Plus Valacyclovir Well Tolerated; Grade 3 Adverse Events in 13.7% of Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672275404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672275404?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.0705},{"period":"1month","weight":-0.1854},{"period":"3month","weight":-0.2408},{"period":"6month","weight":-0.0371},{"period":"1year","weight":0.5796},{"period":"ytd","weight":0.423}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.18781},{"month":6,"riseRate":0.2,"avgChangeRate":-0.088023},{"month":7,"riseRate":0.2,"avgChangeRate":0.003189},{"month":8,"riseRate":0.833333,"avgChangeRate":0.108437},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.047745},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.125556},{"month":11,"riseRate":0,"avgChangeRate":-0.072251},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}